Inhalon Biopharma is a clinical-stage biotechnology company with a precedent-setting pulmonary drug delivery platform to treat patients suffering from acute respiratory infections such as RSV, influenza, hMPV and SARS-CoV-2. Inhalon’s patented, proprietary technology platform enhances mucosal immunity by leveraging the mucosal clearing properties of the respiratory tract and the neutralizing properties of antibodies to physically clear viruses from the airways. Inhalon is developing inhaled, outpatient treatments for respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV) and SARS. Patients will be able to self-administer the treatment in the convenience of their own home. We have raised over $45M through private equity ($10M) and awards/grants ($36M) and are raising $50M to fund the development of our RSV candidate through a phase 2 proof-of-concept human challenge study and to file two additional INDs.